secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0000950170-25-014464
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics reports FY2024 net loss $110M; cash $903M; Phase 3 VK2735 planned 2Q25
--------------------------------------------------------------------------------

- Net loss $110.0M ($1.01 per share) for FY2024, compared to net loss $85.9M ($0.91 per share) in 2023.
- Cash, cash equivalents and short-term investments of $903M as of Dec 31, 2024, up from $362M a year earlier.
- Initiation of Phase 3 studies for subcutaneous VK2735 in obesity planned for 2Q25 after FDA End-of-Phase 2 meeting.
- Phase 2 VENTURE-Oral trial of VK2735 tablet underway in ~280 obese subjects; data expected 2H25.
- Phase 2b VOYAGE in MASH: VK2809 showed MASH resolution rates up to 75% vs 29% placebo, and fibrosis improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/0000950170-25-014464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-20250205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-014464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer